ERBB2 and breast cancer: The results showed that the overall response rate and progression-free survival of pyrotinib+capecitabine were better than lapatinib in patients with HER-2-positive breast cancer who had failed previous taxane, anthracycline and/or trastuzumab therapy Ni+capecitabine [18].